Effect of canagliflozin treatment on β-cell responsiveness in insulin-dysregulated horses: a 4-week, multi-arm, double-blind, randomized clinical trial
Journal of Veterinary Internal Medicine · 01.09.2026 · 40 (5)
DOI: 10.1093/jvimsj/aalag249 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 07.10.2026. Verfasst von Elin Svonni und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Swedish University of Agricultural Sciences, 756 51 Uppsala, Sweden. Hauptthemen laut MEDLINE: Canagliflozin, Horse Diseases, Hyperinsulinism, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish-Norwegian Foundation for Equine Research.
Abstract (Originalsprache)
Background
The sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin (CAN) decreases hyperinsulinemia in insulin-dysregulated (ID) horses, but its effects on pancreatic β-cell responsiveness to glucose are unknown. Hypothesis/Objectives Compare the effects of 2 CAN dosages (0.6 and 1.2 mg/kg) with placebo (PBO) on β-cell responsiveness to IV glucose in ID horses using a graded glucose infusion (GGI) test. Animals Forty-two privately-owned ID horses.
Methods
Randomized, multicenter, double-blind, parallel-group, multi-arm, PBO-controlled study. Horses underwent GGI testing before and after 4 weeks of treatment with PO CAN (0.6 or 1.2 mg/kg) or PBO. Indices of β-cell responsiveness included the slope of insulin vs glucose relationship (ΔI vs ΔG) and the ratio of the incremental areas under the curve for insulin and glucose (iAUCINS/iAUCGLU).
Results
Least squares (LS) means ± SEM ΔI vs ΔG values were lower with CAN (0.6 and 1.2 mg/kg) than with PBO (P ≤ .001; 22.0 ± 3.5 and 21.1 ± 3.2 mIU/mmol vs 38.4 ± 3.3 mIU/mmol) with no difference between CAN dosages (P = .96). Geometric LS mean (95% CI) iAUCINS/iAUCGLU values were lower with CAN (0.6 and 1.2 mg/kg) compared with PBO (P ≤ .001; 19.3 [16.5-22.5] and 16.4 [13.9-19.3] mIU/mmol vs 33.1 [28.4-38.7] mIU/mmol). Conclusions and clinical importance Canagliflozin decreased β-cell responsiveness to IV glucose in ID horses, representing a key mechanism underlying the hyperinsulinemia-decreasing effect of SGLT2 treatment in horses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, 756 51 Uppsala, Sweden.
- Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences, 1430 Ås, Norway.
ORCID-Profile: Elin Svonni, Sanna Lindåse, Siv Hanche-Olsen, Ingunn Risnes Hellings, Constanze Fintl, Katarina Nostell, Johan Bröjer
Förderung
- Swedish-Norwegian Foundation for Equine Research
Zitieren
APA
Svonni, E., Lindåse, S., Hanche-Olsen, S., Hellings, I. R., Fintl, C., Nostell, K., & Bröjer, J. (2026). Effect of canagliflozin treatment on β-cell responsiveness in insulin-dysregulated horses: a 4-week, multi-arm, double-blind, randomized clinical trial. Journal of Veterinary Internal Medicine, 40(5). https://doi.org/10.1093/jvimsj/aalag249
Vancouver
Svonni E, Lindåse S, Hanche-Olsen S, Hellings IR, Fintl C, Nostell K, et al. Effect of canagliflozin treatment on β-cell responsiveness in insulin-dysregulated horses: a 4-week, multi-arm, double-blind, randomized clinical trial. Journal of Veterinary Internal Medicine. 2026;40(5). doi:10.1093/jvimsj/aalag249
BibTeX
@article{Svonni2026,
author = {Svonni, Elin and Lindåse, Sanna and Hanche-Olsen, Siv and Hellings, Ingunn Risnes and Fintl, Constanze and Nostell, Katarina and Bröjer, Johan},
title = {Effect of canagliflozin treatment on β-cell responsiveness in insulin-dysregulated horses: a 4-week, multi-arm, double-blind, randomized clinical trial},
journal = {Journal of Veterinary Internal Medicine},
year = {2026},
volume = {40},
number = {5},
doi = {10.1093/jvimsj/aalag249}
}
EUVIMED